Comparing a RCC trial to a Sarcoma trial is pointless. But how about an apples to apples comparison - how did the Afinitor data just released at ASCO stack up against Ridaforolimus in Sarcoma? Well, in one arm, Rida had more than TWICE the efficacy as Afinitor - 13% vs 29%. So as much as you want to make the case that other mTOR's are "better" than rida, the facts don't support your opinion. Again, please feel free to point me to any results that support your claim that there are other therapies farther along than rida that will work better in Sarcoma.
News 
Market Data 
Discover 
AI
